Global Health Limited (MEDANTA)
🎯 Key Takeaways
- Global Health Limited is in a high-growth phase driven by aggressive hospital expansion and volume-led revenue growth, transitioning from a mature healthcare services provider to a scaling player with national ambitions. Management is prioritizing capacity augmentation and digital transformation, evidenced by new hospital openings, bed capacity expansions, and leadership hires in digital functions.
- Revenue declined 1.4% QoQ to ₹943 in Q3FY25.
- ⚠️ Execution risk in hospital ramp-ups: New facilities in Indore and Guwahati may face delays or cost overruns, impacting financial targets.
📖 The Story
Global Health Limited is in a high-growth phase driven by aggressive hospital expansion and volume-led revenue growth, transitioning from a mature healthcare services provider to a scaling player with national ambitions. Management is prioritizing capacity augmentation and digital transformation, evidenced by new hospital openings, bed capacity expansions, and leadership hires in digital functions. However, profitability pressures persist as operational scale has not yet translated into proportional margin gains, particularly in PAT performance.
📰 What's Happening
In Q1 FY27, the company reported consolidated total income of ₹13,262 crores, up 26.2% YoY, fueled by strong volume growth and improved realisations, with occupancy rising to 62.6% and ARPOB at ₹70,244. A key development was the board-approved expansion of the Guwahati hospital project from 400 to 650 beds with a Rs 970 crore investment, alongside the operationalisation of an 80-bed cancer facility in Indore in the coming months. The company also appointed Pradeep Kumar Singh as Chief Digital Officer effective July 30, 2026, as part of its long-term incentive and talent retention strategy, including a grant of 20,000 ESOPs under the GHL LTIP 2024 Plan.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 703 | 773 | 844 | 833 | 809 | 861 | 957 | 943 |
| Operating Profit | 192 | 199 | 234 | 234 | 207 | 208 | 247 | 254 |
| OPM % | 23.2% | 23.0% | 25.2% | 25.5% | 22.2% | 21.6% | 23.9% | 25.2% |
| Net Profit | 101 | 102 | 125 | 124 | 127 | 106 | 131 | 143 |
| EPS | ₹3.77 | ₹3.80 | ₹4.66 | ₹4.61 | ₹4.74 | ₹3.96 | ₹4.87 | ₹5.32 |
Revenue growth has accelerated significantly, with Q1 FY27 revenue at ₹13,262 crores reflecting 26.2% YoY growth, up from ₹809 crores in Q4 FY24, indicating robust top-line momentum. However, PAT declined 1.1% YoY to ₹1,573 crores in Q1 FY27, attributed to a one-time reversal of interest liability in the prior year, masking underlying operational pressures. While EBITDA grew 23.5% YoY, the margin expansion has not been sufficient to offset rising capital expenditures tied to hospital ramp-ups, suggesting that profitability may remain volatile during the expansion phase.
🔮 Management Outlook & What's Next
Management expects to operationalise an 80-bed cancer facility in Indore in the next few months and scale the Guwahati project to 650 beds over 3-4 years with a Rs 970 crore capex, primarily funded through internal accruals and debt. The board has expressed confidence in sustaining growth through capacity additions and improved realisations, while also emphasizing digital transformation via the new CDO appointment to enhance operational efficiency and patient engagement.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Healthcare Services
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | 1.16 L Cr | 64.5 | 20.5% | 21.9% | 0.64 |
| Max Healthcare Institute Limited | 1.02 L Cr | 101.2 | — | — | — |
| Fortis Healthcare Limited | 72,752 | 94.6 | — | — | — |
| Aster DM Healthcare Limited | 39,048 | 7.1 | — | — | — |
| Narayana Hrudayalaya Ltd. | 37,625 | 47.7 | — | — | — |
| Global Health Limited | 33,405 | 65.8 | — | — | — |
| Krishna Institute of Medical Sciences Limited | 30,477 | 80.3 | — | — | — |
| Dr. Lal Path Labs Ltd. | 26,871 | 63.6 | — | — | — |
| Syngene International Limited | 18,295 | 36.3 | — | — | — |
| Dr. Agarwal's Health Care Limited | 14,266 | 88.8 | 14.9% | 6.8% | 0.13 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Execution risk in hospital ramp-ups: New facilities in Indore and Guwahati may face delays or cost overruns, impacting financial targets. 2. Margin pressure: Despite revenue growth, PAT declined and EBITDA growth was modest, indicating challenges in converting volume into profit. 3. Capex intensity: The Rs 970 crore investment in Guwahati and new projects increases financial exposure without guaranteed return timelines.
📋 Recent Filings
-
Announcement 31 July 2026Global Health Limited announced that an audio recording of its earnings conference call for the first quarter ended June 30, 2026, held on July 31, 20...
-
🔴 Corporate Action 30 July 2026Global Health Limited announced on July 30, 2026, that its board approved unaudited Q1 FY26 financial results, declared a final dividend of Rs 0.50 pe...
-
🔴 Announcement 30 July 2026Global Health Limited announced on July 30, 2026, that its Nomination and Remuneration Committee approved the grant of 20,000 employee stock options u...
-
🔴 Financial Results 30 July 2026Global Health Limited reported Q1 FY2027 consolidated total income of **₹13,262 crores**, up 26.2% YoY, with EBITDA at **₹3,153 crores** (23.5% YoY gr...
-
🟡 Board Meeting 30 July 2026Global Health Limited announced the outcome of its board meeting on July 30, 2026, approving unaudited Q1 financial results, declaring a final dividen...
-
Announcement 30 July 2026Global Health Limited reported Q1 FY27 results showing 26% year-on-year revenue growth to INR 13,262 million, driven by 27.7% in-patient volume increa...
-
Announcement 30 July 2026Global Health Limited announced its Q1 FY26 unaudited financial results, declared a final dividend of Rs 0.50 per share for FY26 payable after the Sep...
-
Announcement 30 July 2026Global Health Limited announced its Q1 FY26 unaudited standalone and consolidated financial results, approved the 22nd AGM for September 16, 2026, dec...
-
Announcement 24 July 2026Global Health Limited announced its Q1 FY2027 earnings conference call scheduled for July 31, 2026 at 2:00 PM IST, hosted by JM Financial, featuring m...
-
🔴 Corporate Action 24 June 2026Global Health Limited announced the allotment of 4,000 equity shares of Rs 2 face value at a premium of Rs 1,287 per share to its ESOP Trust under the...
🧠 Analyst's Read
Global Health Limited is executing a clear expansion strategy with strong top-line momentum, but profitability remains sensitive to the pace and cost of hospital rollouts. Investors should monitor the operational performance of new facilities and the pace of margin recovery in upcoming quarters.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-03.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when MEDANTA files new disclosures
Track MEDANTA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track MEDANTA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research